Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Roche ( OTCQX:RHHBY +0.6% ) unit Spark Therapeutics reports updated data from three dose cohorts in a Phase 1/2 clinical trial evaluating gene therapy candidate SPK-8011 in hemophilia A patients. The results were presented virtually at the International Society of Thrombosis and H...
Roche ( OTCQX:RHHBY +0.4% ) will collaborate with Summit Cancer Centers to explore the use of clinical decision support tools and artificial intelligence-based approaches to the management of patient health information aimed at personalized patient care. More news on: Roche Holding AG,...
July 13, 2020 FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – July 13, 2020 – Coronavirus cases continue to rise in the US this month as regulations lift, causing overambitious governors in several states to backpedal on previous cl...
INDIANAPOLIS , July 13, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the formation of a collaboration with Summit Cancer Centers to explore the use of clinical decision support tools and artificial intelligence-type approaches to the management of patient h...
Roche ( OTCQX:RHHBY ) unit Genentech announces that its Phase 3 clinical trial, IMagyn050 , evaluating the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not meet the co-primary endpoint of progression-free survival (PFS) for the first-l...
Foreword This article is based on five Kiplinger investing articles, plus one from Barron's Weekly, aimed at survival qualities endemic to our-times: Pros' Picks: The 15 Best Nasdaq Stocks , by Dan Burrows, published 5/13/20, "screened the Nasdaq Composite for stocks followed by ...
– Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from Phase III HAVEN studies, with no new safety signals identified – – STASEY is the largest open-label study primarily assessing safety and tolerability of a ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq ® (atezolizumab) to Avastin ® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-fr...
All five participants in the 5x10 11 vg/kg and 1×10 12 vg/kg dose cohorts and seven participants in the 2×10 12 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and substantial improvement in annualized bleed rate (ABR) after between two ...
Thermo Fisher Scientific (NYSE: TMO ) inks an agreement with Roche ( OTCQX:RHHBY ) unit Chugai Pharmaceutical Co., Ltd. to expand the use of TMO's Oncomine Dx Target Test as a companion diagnostic to identify ROS1-positive non-small cell lung cancer patients who may be suitable for Roche's...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options – – Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Onc...
Roche and Hitachi High-Tech extend their long-standing partnership TOKYO, May 28, 2024 - (JCN Newswire) - Hitachi High-Tech Corporation announced that Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration. Bringing t...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for ...